DSGN

Design Therapeutics Inc.

Price

$15.94

return (12m)

208.32%

p/e

-12.83

p/bv

4.50

DIVIDEND YIELD

0.00%

DSGN price

Design Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment DSGN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

33.72%

3 months

44.78%

1 year

208.32%

2 years

235.58%

5 years

6.55%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals DSGN

Valuation

P/E

-12.83

Sector -4.38

Industry -4.38

P/BV

4.50

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-31.82

Sector -263.09

Industry -263.09

EV/EBIT

-31.61

Sector -702.90

Industry -702.90

P/EBITDA

-11.54

Sector -4.39

Industry -4.39

P/EBIT

-11.45

Sector -4.73

Industry -4.73

P/Total Assets

4.22

Sector 1.49

Industry 1.49

P/Net Current Assets

4.57

Sector -11.70

Industry -11.70

P/Working Capital

4.52

Sector -3.19

Industry -3.19

EPS

-1.12

Sector -2.14

Industry -2.14

BVPS

3.20

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-35.07%

Sector -65.14%

Industry -65.14%

ROA

-32.91%

Sector -65.53%

Industry -65.53%

ROIC

-1,386.06%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

18.86

Sector 2.90

Industry 2.90

Net Debt / EBITDA

9.41

Sector -6.07

Industry -6.07

Net Debt / EBIT

9.35

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.03

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.94

Sector 0.41

Industry 0.41

Liabilities/Assets

0.06

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

14.79%

Sector -

Industry -

Fundamentals DSGN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
DSGN Design Therapeutics Inc.	$15.94	195.19%	0.00%	-12.83	4.50	-35.07%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

DSGN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Design Therapeutics

Design Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

9 years

Founded: 2017

2021

Time since IPO - 5 years

22

Employees

Design Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $908.46 million, with shareholders equity totaling $201.86 million.

The company employs approximately 22 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Design Therapeutics Inc. reported $- in revenue, generating net income of $-70.80 million.

Key financial metrics include a P/E ratio of -12.83, a price-to-book (P/B) ratio of 4.50, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker DSGN.

Market cap

$908.46 million

Net worth

$201.86 million

$201,860,000.00

Assets

$215.13 million

$215,130,000.00

Total Shares Outstanding

63.00 million

63,000,000

Average Daily Trading Volume

$705.25 Thousand

$705,246.00

Sector

Health Care

Industry

Biotechnology

DSGN

DSGN revenue and profits

Financial Results DSGN

DRAG THE FRAME TO SEE MORE DATA

DSGN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Design Therapeutics (DSGN) today?

A cotação de Design Therapeutics (DSGN) hoje está em US$ 15.94, com uma variação de 208.32% em relação ao último ano. A cotação de Design Therapeutics (DSGN) iniciou o ano negociando na casa dos US$ 9.38 e hoje está em US$ 15.94. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Design Therapeutics (DSGN) e dados de ações do Ibovespa e mercados internacionais.

Quando Design Therapeutics (DSGN) paga dividendos?

Design Therapeutics (DSGN) não distribuiu dividendos no último ano.

Is Design Therapeutics (DSGN) a good investment?

Atualmente, Design Therapeutics (DSGN) está cotada a US$ 15.94, com um P/L de -12.83, representando um desvio de -790% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 208.32 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 208.32%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Design Therapeutics (DSGN) stock?

Investir em ações de Design Therapeutics (DSGN) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Design Therapeutics (DSGN) yield today?

A rentabilidade de Design Therapeutics (DSGN) foi de 33.72% no último mês, 208.32% no último ano e 6.55% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Design Therapeutics (DSGN) hoje, o investimento total seria de US$ 1,594.00, com base na cotação atual de US$ 15.94.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 4,914.62
Em 5 anos: US$ 1,698.41
Em 10 anos: US$ 1,594.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

DSGN

Design Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment DSGN

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING DSGN WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Design Therapeutics

Design Therapeutics Inc.

United States

9 years

2021

22

PROFIT X PRICE DSGN

Financial Results DSGN

DSGN cash flow

Asset, Revenue and Profit Growth - DSGN

DSGN balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions